Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Bitter Pill? Researchers Challenge Citrus Aurantium Safety, Efficacy

This article was originally published in The Tan Sheet

Executive Summary

The inclusion of Citrus aurantium in weight-loss products is not supported by substantial clinical evidence, researchers conclude in the September issue of Experimental Biology & Medicine

You may also be interested in...

Chattem Shipments Of Dexatrim With Bitter Orange To Halt In May

Chattem's impending exit from the bitter orange weight-loss market may be a bellwether for industry, as was the firm's departure from the ephedra business

Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms

A 1final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids will become effective April 12, FDA announced Feb. 6

FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban

FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts